apomorphine has been researched along with alpha-synuclein in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Mandel, S; Maor, G; Youdim, MB | 1 |
| Chesselet, MF; Fleming, SM; Hutson, CB; Levine, MS; Masliah, E; Rockenstein, E; Salcedo, J | 1 |
| Debetto, P; Giusti, P; Guidolin, D; Negro, A; Peroni, D; Recchia, A; Rota, D; Skaper, SD | 1 |
| Johansson, SM; Modo, MM; Vernon, AC | 1 |
| Bähr, M; Garrido, M; Kügler, S; Taschenberger, G; Tereshchenko, Y; Zhevtsova, Z | 1 |
| An, CN; Pu, XP; Sun, SY | 1 |
| Brekk, OR; Kirik, D; Landeck, N; Papadopoulou-Daifoti, Z; Papasilekas, T; Pitychoutis, PM; Stefanis, L; Xilouri, M | 1 |
| Aebischer, P; Bensadoun, JC; Coune, PG; Schneider, BL | 1 |
| Bao, XQ; Kong, LB; Kong, XC; Sun, H; Wu, LY; Zhang, D | 1 |
| Auburger, G; Bez, F; Brehm, N; Carlsson, T; Cenci, MA; Gispert, S; Kern, B | 1 |
| Deng, Y; Lu, J; Ma, H; Qing, H; Sun, F | 1 |
| Chen, NH; Chu, SF; Li, J; Liu, Y; Song, LK; Sun, JD; Yuan, YH | 1 |
| Li, K; Li, Y; Na, S; Wu, J; Xie, X; Yang, J; Yang, Z; Yu, X; Yue, J | 1 |
| Felten, P; Heurtaux, T; Kirchmeyer, M; Koncina, E; Mittelbronn, M; Richart, L; Schohn, H; Uriarte Huarte, O | 1 |
| Abuleil, A; Ajagbe, AO; Alhendawi, BHM; Badri, R; Chaaya, C; Chalhoub, E; Korkusuz, AK; Onyeaka, H; Uwishema, O; Yücel, AN | 1 |
| Mohajeri, D; Nourazar, MA; Sokouti, H | 1 |
16 other study(ies) available for apomorphine and alpha-synuclein
| Article | Year |
|---|---|
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apomorphine; Catechin; Disease Models, Animal; Free Radicals; Iron; Iron Chelating Agents; Lewy Bodies; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Substantia Nigra; Synucleins; Ubiquitin | 2004 |
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Stereotypic Movement Disorder | 2006 |
Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Gene Expression Regulation; Gene Products, tat; Genetic Vectors; Green Fluorescent Proteins; Male; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Apomorphine; Corpus Striatum; Cysteine Proteinase Inhibitors; Disease Models, Animal; Dopamine; Dopamine Agonists; Iron; Magnetic Resonance Imaging; Male; Mesencephalon; Motor Activity; Neurons; Parkinsonian Disorders; Random Allocation; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2010 |
Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Apomorphine; Catalytic Domain; Cell Survival; Cysteine; Disease Models, Animal; Dopamine; Dopamine Agonists; Female; Gene Expression Regulation; Gliosis; Glutathione; Glutathione Reductase; Green Fluorescent Proteins; Movement; Nerve Degeneration; Rats; Rats, Wistar; RNA, Small Interfering; Sensation Disorders; Stereotyped Behavior; Substantia Nigra; Time Factors; Transduction, Genetic; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2011 |
DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Dopaminergic Neurons; Drug Evaluation, Preclinical; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Ion Channels; Leupeptins; Male; Microinjections; Mitochondrial Membrane Transport Proteins; Mitochondrial Proteins; Mitochondrial Uncoupling Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Oncogene Proteins; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Protein Deglycase DJ-1; Rats; Rats, Sprague-Dawley; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2012 |
Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Apomorphine; Autophagy; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Dependovirus; Dopamine; Embryo, Mammalian; Enzyme Inhibitors; Female; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Hemagglutinins; Humans; Lysosomal Membrane Proteins; Lysosomal-Associated Membrane Protein 2; Macrolides; Mice; Molecular Chaperones; Motor Activity; Nerve Degeneration; Neuroblastoma; Neurons; Rats; Transfection; Tyrosine 3-Monooxygenase | 2013 |
Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apomorphine; Disease Models, Animal; Dopaminergic Neurons; Exploratory Behavior; Female; Forelimb; Genetic Vectors; Golgi Apparatus; Humans; Male; Mice; Mutation; Parkinson Disease; rab1 GTP-Binding Proteins; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2011 |
Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
Topics: alpha-Synuclein; Animals; Apomorphine; Benzeneacetamides; Cell Death; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phenols; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Repressor Proteins; Signal Transduction; Transcription Factors; Tyrosine 3-Monooxygenase | 2014 |
A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.
Topics: alpha-Synuclein; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Humans; Locomotion; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mutation, Missense; Nerve Tissue Proteins; Parkinsonian Disorders; Phosphorylation; Point Mutation; Post-Synaptic Density; Prions; Promoter Regions, Genetic; Protein Processing, Post-Translational; Stereotyped Behavior; Substantia Nigra; Transgenes | 2015 |
Comparison between α-synuclein wild-type and A53T mutation in a progressive Parkinson's disease model.
Topics: Age Factors; alpha-Synuclein; Amino Acid Substitution; Animals; Apomorphine; Brain; Disease Models, Animal; Dopaminergic Neurons; Immunohistochemistry; Male; Mutant Proteins; Mutation, Missense; Parkinsonian Disorders; Phosphorylation; Protein Aggregation, Pathological; Rats; Rats, Transgenic; Rats, Wistar; Recombinant Proteins; Torsion Abnormality | 2015 |
Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apomorphine; Body Weight; Brain; Disease Progression; Dopamine; Dopamine Agonists; Enteric Nervous System; Environmental Exposure; Housing, Animal; Male; Mice, Inbred C57BL; Motor Activity; Muscle, Skeletal; Neurons; Olfactory Perception; Parkinsonian Disorders; Rotenone; Tyrosine 3-Monooxygenase | 2015 |
The Protective Role of Brain CYP2J in Parkinson's Disease Models.
Topics: alpha-Synuclein; Animals; Apomorphine; Brain; Cell Line, Tumor; Chromatin Immunoprecipitation; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dopaminergic Neurons; Humans; Lipopolysaccharides; Male; Myeloid Differentiation Factor 88; NF-E2-Related Factor 2; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Signal Transduction; Toll-Like Receptor 4 | 2018 |
Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway.
Topics: alpha-Synuclein; Animals; Antioxidants; Apomorphine; Dopamine; Dopamine Agonists; Free Radical Scavengers; Humans; Mice; Microglia; NF-E2-Related Factor 2; Parkinson Disease; RNA, Small Interfering | 2022 |
The understanding of Parkinson's disease through genetics and new therapies.
Topics: alpha-Synuclein; Apomorphine; Dopaminergic Neurons; Humans; Hypokinesia; Parkinson Disease; Tremor | 2022 |
6-Hydroxydopamine-Induced Neurotoxicity in Rat Model of Parkinson's Disease: Is Reversed via Anti-Oxidative Activities of Curcumin and Aerobic Exercise Therapy.
Topics: alpha-Synuclein; Animals; Antioxidants; Apomorphine; Curcumin; Disease Models, Animal; Glutathione Peroxidase; Malondialdehyde; Neuroprotective Agents; Neurotoxicity Syndromes; Neurotoxins; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra | 2022 |